DE framework in Large Healthcare Corporations
Chetan Thakkar asked 4 years ago
Hi,
I am fascinated by Bill Aulet’s drive for making Large Corporations more Entrepreneurial. I work with one such large corporate in healthcare space and would like to know the following:
- Which are the large healthcare problems that Bill addresses in some of his speeches?
- Is there a way for individuals to get involved in solving these problems? If so, how?
I look forward to work closely with DE group in the spirit of “Mens et Manus” 🙂
Bill Aulet answered 4 years ago
Healthcare in general falls into 3 broad categories:
- Digital Healthcare — companies like PillPack adn Podometrics (which both came out of our center) and many more. that you can find in Hacking Medicine @ MIT. This is generally the digitization of processes in the field to produce better and cheaper positive outcomes.
- Medical Devices — this is where there is a physical device that incorporates some advanced technology to improve healthcare.
- BioTech — producing new drugs.
All of these areas benefit from the DE approach but from my perspective it applies best to #1 (as seen by the results to date) and then followed by #2 and then #3. Honestly, I don’t completely understand how it applies to #3 but biotech people tell me that it does.
With regard to #2 above, Paul Yok’s work that he developed in the Stanford BioDesign group has been highly recommended to me and I would look at that as well.
Bill
Bill Aulet answered 4 years ago
Healthcare in general falls into 3 broad categories:
- Digital Healthcare — companies like PillPack adn Podometrics (which both came out of our center) and many more. that you can find in Hacking Medicine @ MIT. This is generally the digitization of processes in the field to produce better and cheaper positive outcomes.
- Medical Devices — this is where there is a physical device that incorporates some advanced technology to improve healthcare.
- BioTech — producing new drugs.
All of these areas benefit from the DE approach but from my perspective it applies best to #1 (as seen by the results to date) and then followed by #2 and then #3. Honestly, I don’t completely understand how it applies to #3 but biotech people tell me that it does.
With regard to #2 above, Paul Yok’s work that he developed in the Stanford BioDesign group has been highly recommended to me and I would look at that as well.
Bill